on July 28, 2008
Published online before print July 28, 2008, doi: 10.1161/CIRCULATIONAHA.107.736801
Submitted on October 16, 2007
From the Department of Physiology and Functional Genomics, Shands Cancer Center, University of Florida College of Medicine, Gainesville (K.-H.H., Y.J.L., E.L., S.O.P., C.H., M.K.R., S.P.O.); Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, Republic of Korea (Y.J.L., S.P.O.); Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown (H.B., E.L., K.D.B.); and Anesthesia Center for Critical Care Research, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston (H.B., K.D.B.). * To whom correspondence should be addressed. E-mail: ohp{at}phys.med.ufl.edu.
Background—Pulmonary arterial hypertension (PAH) is a rare but fatal lung disease of diverse origins. PAH is now further subclassified as idiopathic PAH, familial PAH, and associated PAH varieties. Heterozygous mutations in BMPR2 can be detected in 50% to 70% of patients with familial PAH and 10% to 40% of patients with idiopathic PAH. Although endothelial cells have been suspected as the cellular origin of PAH pathogenesis, no direct in vivo evidence has been clearly presented. The present study was designed to investigate whether endothelial Bmpr2 deletion can predispose to PAH. Methods and Results—The Bmpr2 gene was deleted in pulmonary endothelial cells using Bmpr2 conditional knockout mice and a novel endothelial Cre transgenic mouse line. Wide ranges of right ventricular systolic pressure were observed in mice with heterozygous (21.7 to 44.1 mm Hg; median, 23.7 mm Hg) and homozygous (20.7 to 56.3 mm Hg; median, 27 mm Hg) conditional deletion of Bmpr2 in pulmonary endothelial cells compared with control mice (19.9 to 26.7 mm Hg; median, 23 mm Hg) at 2 to 7 months of age. A subset of mice with right ventricular systolic pressure >30 mm Hg exhibited right ventricular hypertrophy and an increase in the number and wall thickness of muscularized distal pulmonary arteries. In the lungs of these mice with high right ventricular systolic pressure, the expression of proteins involved in the pathogenesis of PAH such as serotonin transporter and tenascin-C was elevated in distal arteries and had a high incidence of perivascular leukocyte infiltration and in situ thrombosis. Conclusions—Conditional heterozygous or homozygous Bmpr2 deletion in pulmonary endothelial cells predisposes mice to develop PAH.
Accepted on June 5, 2008
Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension
Kwon-Ho Hong PhD,
Key words: endothelium • genetics • hypertension, pulmonary • receptors
Related Article:
Circulation 2008 118: 697-698.
This article has been cited by other articles:
 |
|
 |
|
  K. R. Stenmark, B. Meyrick, N. Galie, W. J. Mooi, and I. F. McMurtry Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1013 - L1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guignabert, C. M. Alvira, T.-P. Alastalo, H. Sawada, G. Hansmann, M. Zhao, L. Wang, N. El-Bizri, and M. Rabinovitch Tie2-mediated loss of peroxisome proliferator-activated receptor-{gamma} in mice causes PDGF receptor-{beta}-dependent pulmonary arterial muscularization Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1082 - L1090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. Lloyd Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S20 - S31. [Abstract] [Full Text] [PDF]
|
|